Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival is a paper indexed in PICO Portal from OpenAlex.
How many citations does Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival have?
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival has 245 citations in the OpenAlex counts PICO Portal stores.
When was Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival published?
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival has 2008 year in the PICO Portal index.
What is the open-access status of Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival?
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival has closed oa status in the PICO Portal index.
What is the DOI of Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival?
The DOI for Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival is on the source record.
What is the PMID of Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival?
The PMID for Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival is on the source record.
What is the OpenAlex record for Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival?
The OpenAlex for Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival is on the source record.